Safran is one of the top picks in our European aerospace and defense coverage. The group is trading on a price/fair value estimate ratio of 0.72 times and is the cheapest wide-moat stock among its global commercial aerospace peers under our coverage based on this metric. The coronavirus pandemic hit earnings hard, with first-half 2021 EBIT still 65% below 2019 levels. The share price remains 30% below the prepandemic high of EUR 150 recorded in February 2020. We believe Safran is well positioned for a recovery and benefits from structural underlying market growth drivers over the longer term. Aftermarket sales, which are core to group profitability, should recover by 2024 driven by a recovery in domestic air traffic. We don’t anticipate a surge in narrow-body aircraft retirements due to the relatively young fleet and market factors, which limits the scope for a surge in retirements. After the recovery, the group should grow ahead of the market due to its dominant share of narrow-body aircraft programs, which are expected to gain share at the expense of wide-body aircraft. The recovery is more certain than the path to recovery and investors who have been persistently bombarded with news of new virus variants, spikes in infection rates and haphazard easing and reintroduction of travel restrictions are feeling once bitten, twice shy. Until the market gains confidence in the recovery, it will overly discount near-term risks at the expense of long-term prospects. We believe the payoff is asymmetric, with risk skewed to the upside, and a sufficient margin of safety exists for investors who are looking to acquire or add to a moaty, long-cycle business with a high share of recurring revenue.